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methotrexate both in severe and highly active RA.
METHODS:
A lifetime deterministic Markov model was developed comparing two treatment sequences within two hypothetical cohorts of patients. Five to six treatment sequences were considered in each arm. Patients switched to the next sequence in case of lack of effectiveness or in case of severe adverse events. Patients' health status was defined by the Health Assessment Questionnaire (HAQ), scale which demonstrated strong links with mortality and quality of life. Scores were updated at every six-month model cycles. Treatment failure occurred if the score did not improve by 0.35 point over the cycle. HAQ scores were converted into utility coefficients. Effectiveness data (HAQ progression, serious adverse events and mortality) were derived from TEMPO trial and literature. Only direct medical costs were considered. Resource use was estimated through published data and expert opinion. Costs were derived from French official sources. Sensitivity analyses were performed on main model parameters.
RESULTS:
The results showed that QALYs (Quality-Adjusted Life-Years) were increased respectively in severe and highly active RA by 0.98 (9.10vs8.12) and 0.73 (10.52vs9.78) 
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IMPACT OF MEDICATION NON-COMPLIANCE AND NON-PERSISTENCE ON PHARMACOECONOMIC EVALUATIONS IN OSTEOPOROSIS
Hiligsmann M, Rabenda V, Gathon HJ, Ethgen O, Reginster JY University of Liège, Liège, Belgium OBJECTIVES: Poor compliance and failure to persist with drug therapy are of potential economic significance. The objective of this study is to assess the impact of medication non-compliance and non-persistence on economic evaluations in osteoporosis. METHODS: A Markov microsimulation model with a lifetime horizon and a societal perspective was used to analyse the impact of non-adherence to biphosphonate therapy on costs (drug, disease and total), on outcomes (Quality-Adjusted Life Years and number of fractures saved) and on the cost-utility of biphosphonate therapy versus no treatment. Analyses were performed for caucasian women aged 70 years with a diagnosis of osteoporosis (t-score Յ -2.5). The relationship between compliance and fracture efficacy were taken from published sources and drug cost was proportionate to compliance level. To model persistence to therapy, we assumed that women can stop therapy after 3 months, 6 months, 1 year, 2 years or 3 years. RESULTS: Full adherence to therapy resulted in a QALY gain of 0.0397, a 7.6% reduction in the number of fractures and a higher cost of €383 compared to no treatment. Lower compliance was associated with a decrease in QALY gain, a reduction in the number of fractures saved and a higher disease cost compensated by a lower drug cost. The cost per QALY gained for biphosphonate therapy versus no treatment increased progressively with decreasing compliance and was €9,653 €29,570 and €46,389 at 100%, 50% and 20% of compliance respectively. Realistic persistence assumption (with full compliance) resulted in a lower QALY gain (only 0.0165) and a higher cost per QALY gained (€12,479). CON-CLUSIONS: This study indicated that non-compliance and nonpersistence to osteoporotic therapy result not only in worsening health outcomes, but also in a significant change in costeffectiveness. Therefore, the effects of non-compliance and nonpersistence should be an integral part of economic evaluations in osteoporosis.
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COST-EFFECTIVENESS SIMULATION MODEL OF ABATACEPT VERSUS RITUXIMAB IN RHEUMATOID ARTHRITIS IN FRANCE
Gossec L 1 , Goupille P 2 , Saraux A 3 , Bregman B 4 , Boccard E 4 , Dupont D 5 , Beresniak A 6 1 Cochin Hospital, Paris, France, 2 CHRU de Tours-Université François Rabelais, Tours, France, 3 Hôpital de la Cavale Blanche, Brest, France, 4 Bristol-Myers Squibb, Rueil-Malmaison, France, 5 Bristol-Myers Squibb International Corporation, Braine l'Alleud, Belgium, 6 LIRAES, Descartes University, Paris, France and Data Mining International, Geneva, Switzerland OBJECTIVES: New biologic therapies with distinct mechanisms of action offer alternatives to rheumatologists and hope to patients with moderate to severely active rheumatoid arthritis (RA) and an inadequate response to anti-TNF therapy. The objective of this study was to assess the cost-effectiveness of abatacept and rituximab in biologic treatment sequences in patients with RA and an inadequate response to one anti-TNF agent. METHODS: An advanced simulation model was developed to assess the cost-effectiveness of two biologic strategies in etanercept inadequate-responders: Strategy A-abatacept followed by adalimumab (in case of an inadequate response to abatacept); Strategy B-rituximab followed by adalimumab (in case of an inadequate response to rituximab). Two clinically relevant effectiveness endpoints were used: low disease activity state (LDAS) (DAS28 Յ3.2) and remission (DAS28 <2.6). Effectiveness estimates for abatacept and rituximab were derived from published pivotal trials and long-term extension studies, assuming similar patient populations. Overall effectiveness was expressed in theoretical expected number of days (TEND) under remission or LDAS for each sequence after 2 years. French RA direct medical costs were derived from a costing model based on DAS28 categories. Using 4 ¥ 6-month cycles, drug costs were estimated based on recommended dosing. Assuming a sustained response over 6-month cycles, the rituximab re-treatment interval was set at 6 months. Monte-Carlo simulations generated mean values and standard deviations of costs, effectiveness and mean cost-effectiveness over 2 years. Significance tests were performed to confirm differences. RESULTS: Using the LDAS endpoint, Strategy A (abatacept as second biologic agent) was significantly more efficacious over 2 years versus (vs) Strategy B (rituximab as second biologic agent), with 134 vs 107 TEND under LDAS (p < 0.01). Mean cost-effectiveness ratios showed significantly lower overall medical costs per TEND under LDAS with Strategy A vs Strategy B (€212 vs €234; p < 0.01). Using the remission endpoint, Strategy A (abatacept as second biologic agent) was significantly more efficacious over 2 years vs Strategy B (rituximab as second biologic agent), with 61 vs 37 TEND under remission (p < 0.01). Mean cost-effectiveness ratios showed significantly lower overall medical costs per TEND under remission with Strategy A vs Strategy B (€446 vs €642; p < 0.01). CONCLUSIONS: This innovative and robust model is the first to use LDAS and remission to compare biologic strategies in France, aligned with RA treatment goals. The results suggest that when used as the second biologic agent after an inadequate response to one anti-TNF agent, abatacept appears significantly more efficacious and cost-effective than rituximab.This innovative and robust model is the first to use LDAS and remission to compare biologic strategies in France, aligned with RA treatment goals. The results suggest that when used as the second biologic agent after an inadequate response to one anti-TNF agent, abatacept appears significantly more efficacious and cost-effective than rituximab. Costs analyzed: acquisition costs of drugs, drug administration and treatment monitoring costs, adverse events treatment costs, AS hospitalization costs, tuberculosis monitoring and treatment costs. Health outcomes included quality-adjusted life-year (QALY). Data from systematic review of published randomized clinical trials were used to evaluate transition probabilities during anti-TNF-a or comparator (standard AS therapy-NSAID and/or DMARD's) treatment. Utility values were calculated from BASFI, BASDAI, sex and age data based on published algorithm. Costs and effects were discounted 5% annually. Univariate and probabilistic sensitivity analyses were performed. Values are presented in PLN (exchange rate: 1 Euro = 3.40 PLN). RESULTS: In the base-case analysis QALY gains of 0.063 and 0.302 were estimated for patients treated with adalimumab, etanercept or infliximab in 1-year and life-time horizon, respectively. ICER/QALY in one year horizon was 597,455, 597,169 and 796,076 PLN/QALY for adalimumab, etanercept and infliximab, respectively. In life-time horizon ICER/QALY was 405,430, 405,235 and 471,707 PLN/QALY for adalimumab, etanercept and infliximab, respectively. CONCLUSIONS: Anti-TNF-alfa treatment is currently unattractive for all AS patients in polish health care settings, thus further analysis are needed to identify subgroups of patients who benefit most to ensure effective resources allocation.
